All In Biotech

Drug Trial Radar · NCT00559962

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy

Last checked: Nov 20, 2026Latest source record: Feb 23, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

260

Actual

Start

Oct 2007

Primary completion

Oct 2008

Study completion Nov 2008

Sponsor

Lead sponsor
Aegerion Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 19, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy

Conditions

  • Hyperlipidemia

Interventions

  • AEGR-733Drug

    3 capsules each evening for each 4-week period

  • placeboDrug

    3 capsules each evening for each 4-week period

  • AEGR-733Drug

    3 capsules each evening for each 4-week period

  • AEGR-733Drug

    3 capsules each evening for each 4-week period

  • AEGR-733Drug

    3 capsules each evening for each 4-week period

  • AEGR-733 and atorvastatinDrug

    3 capsules each evening for each 4-week period

  • AEGR-733 and fenofibrateDrug

    3 capsules each evening for each 4-week period

  • AEGR-733 and ezetimibeDrug

    3 capsules each evening for each 4-week period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute Change From Baseline in Percent Hepatic FatTime frame: Baseline and 12 weeks on study drug

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Scripps Clinic

    San Diego, California

  • Radiant Research

    Santa Rosa, California

  • MedStar Research Institute

    Washington D.C., District of Columbia

  • Radiant Research

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • LMARC

    Louisville, Kentucky

  • Maine Research Associates

    Auburn, Maine

  • Health Trends Research

    Baltimore, Maryland

  • Johns Hopkins

    Baltimore, Maryland

  • Washington Univ. School of Medicine

    St Louis, Missouri

  • Sterling Research Group

    Cincinnati, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Baylor College of Medicine

    Houston, Texas

  • Clinical Trial Network

    Houston, Texas

  • dgd Research

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.